Opus Genetics FY2025 EPS Forecast Increased by HC Wainwright

Opus Genetics, Inc. (NASDAQ:IRD) – HC Wainwright increased their FY2025 earnings per share estimates for Opus Genetics in a research note issued on Thursday, November 13th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.61) for the year, up from their prior forecast of ($0.63). The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2025 earnings at ($0.09) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.13 EPS.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Opus Genetics had a negative net margin of 377.89% and a negative return on equity of 384.33%. The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $3.07 million.

A number of other research firms also recently issued reports on IRD. Chardan Capital reissued a “buy” rating and issued a $9.00 price target on shares of Opus Genetics in a research note on Thursday, November 13th. Wall Street Zen downgraded Opus Genetics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Wednesday, October 8th. Finally, Wedbush initiated coverage on Opus Genetics in a research report on Wednesday, October 29th. They set an “outperform” rating and a $8.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Opus Genetics currently has an average rating of “Moderate Buy” and a consensus target price of $7.80.

Opus Genetics Trading Up 8.0%

NASDAQ:IRD opened at $1.88 on Monday. The company has a 50-day moving average price of $1.85 and a 200-day moving average price of $1.35. The stock has a market cap of $129.65 million, a price-to-earnings ratio of -0.98 and a beta of 0.16. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.06. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $2.37.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Mink Brook Asset Management LLC boosted its position in shares of Opus Genetics by 3.4% during the third quarter. Mink Brook Asset Management LLC now owns 1,237,947 shares of the company’s stock valued at $2,043,000 after buying an additional 40,331 shares during the last quarter. Citadel Advisors LLC lifted its stake in Opus Genetics by 496.9% during the 3rd quarter. Citadel Advisors LLC now owns 113,416 shares of the company’s stock valued at $187,000 after acquiring an additional 94,416 shares during the period. Creative Planning purchased a new stake in shares of Opus Genetics during the 3rd quarter valued at about $212,000. Raymond James Financial Inc. boosted its holdings in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Opus Genetics by 169.6% in the third quarter. Two Sigma Investments LP now owns 108,338 shares of the company’s stock worth $179,000 after acquiring an additional 68,148 shares during the period. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.